Skip to main content
HSCS
NASDAQ Crypto Assets

Fortitude Buys $1M of HeartSciences Stock at 22% Premium, Reports Strong Q2 Mining Results

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.52
Mkt Cap
$9.924M
52W Low
$1.63
52W High
$3.93
52W Position info
55% above low
Off High info
36% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

HSCS sits 55% above its 52-week low of $1.63 on light trading volume (0.1× avg).

Summary

Fortitude Mining invested $1M in HeartSciences at a 22% premium and reported strong Q2 results, strengthening HeartSciences' balance sheet ahead of their planned merger.


Key Events · Financing and Capital Events · HSCS

  • Fortitude Invests $1M at Premium

    Fortitude purchased 411,522 shares of HeartSciences common stock at $2.43 per share, a 22% premium to the August 12 closing price, for approximately $1,000,000.

  • Fortitude Reports Strong Q2 Results

    Fortitude reported Q2 2026 revenue of $20.9 million and Adjusted EBITDA of $8.5 million, with approximately 33,646 ZEC mined at an average hash rate of 4.0 GSol/s.

  • Fortitude Now Owns 9.4% of HeartSciences

    Following the subscription, Fortitude owns approximately 9.4% of HeartSciences' issued and outstanding common stock.

  • Merger Expected to Close in H2 2026

    The proposed business combination between HeartSciences and Fortitude is expected to close in the second half of 2026, subject to shareholder approval.


Analysis · HSCS · Crypto Assets

Fortitude Mining, the company HeartSciences is merging with, purchased $1 million of HeartSciences stock at $2.43 per share — a 22% premium to the market price on August 12. This is a direct cash infusion into HeartSciences, which has a going concern warning and only $0.2 million in stockholders' equity. The investment supports operating expenses until the merger closes and signals Fortitude's commitment to the deal. Fortitude also reported strong Q2 results: $20.9 million revenue and $8.5 million Adjusted EBITDA, with 33,646 ZEC mined. The premium purchase and solid financials reduce near-term bankruptcy risk for HeartSciences and increase confidence the merger will close.

At the time of this filing, HSCS was trading at $2.52 on NASDAQ in the Crypto Assets sector, with a market capitalization of approximately $9.9M. The 52-week trading range was $1.63 to $3.93. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HSCS - Latest Insights

HSCS
Aug 20, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $2.46
Real-time Price: $2.52 info
Change: +$0.060 (+2%) info
Market Cap: $9.924M info
HSCS
Aug 19, 2026, 5:16 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $2.50
Real-time Price: $2.52 info
Change: +$0.020 (+0.80%) info
Market Cap: $9.924M info
HSCS
Aug 19, 2026, 5:11 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $2.50
Real-time Price: $2.52 info
Change: +$0.020 (+0.80%) info
Market Cap: $9.924M info
HSCS
Aug 19, 2026, 4:47 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $2.45
Real-time Price: $2.52 info
Change: +$0.0715 (+3%) info
Market Cap: $9.924M info
HSCS
Aug 19, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.45
Real-time Price: $2.52 info
Change: +$0.0715 (+3%) info
Market Cap: $9.924M info